Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche publishes trial data for MabThera treatment

Roche publishes trial data for MabThera treatment

21st May 2010

Roche has announced positive results from its recent phase III study of MabThera (rituximab), a follicular lymphoma treatment.

Focusing on patients who responded to initial treatment with MabThera plus chemotherapy, the company found that such patients doubled the likelihood of living without their disease worsening when they continued with the treatment for two years.

After this follow-up period, 82 per cent of the patients who received MabThera were shown to be in remission, compared with 66 per cent of patients who did not receive maintenance.

Hal Barron, executive vice-president of global development and chief medical officer at Roche, suggested that the trial results could be a significant milestone in the treatment of follicular lymphoma.

“The study is important because in those people who continued MabThera, the risk of the cancer progressing was cut in half compared to those who did not receive maintenance MabThera,” he commented.

According to figures from the Lymphoma Coalition, approximately 286,000 people around the world are diagnosed with non-Hodgkin lymphoma, of which follicular lymphoma is a common form, each year.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.